MiR‑1 Reverses Multidrug Resistance in Gastric Cancer Cells Via Downregulation of Sorcin Through Promoting the Accumulation of Intracellular Drugs and Apoptosis of Cells

Overview

Journal Int J Oncol

Specialty Oncology

Date 2019 Jul 4

PMID 31268161

Citations 15

Authors

Lang-Mei Deng

Tan Tan

Tian-Yi Zhang

Xue-Fei Xiao

Huan Gu

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) is one of the most common cancers worldwide and results in the second greatest rate of cancer‑associated mortality globally. Multidrug resistance (MDR) often develops during the chemotherapy, resulting in the failure of treatment. To investigate the molecular mechanism of MDR, the roles of microRNA (miR)‑1 were studied in GC. Reverse transcription‑quantitative polymerase chain reaction and western blotting were used to investigate the expression levels of miR‑1 and sorcin in SGC7901/ADM and SGC7901/VCR cell lines. The effect of miR‑1 on the half maximal inhibitory concentration (IC50), cell apoptosis rates and drug accumulation was uncovered by MTT assay and flow cytometric analysis. Furthermore, dual‑luciferase assay and western blotting were used to determine the target of miR‑1 in GC. It was demonstrated that miR‑1 was highly downregulated in MDR GC cell lines, including SGC7901/ADM and SGC7901/VCR. Overexpression of miR‑1 in MDR GC cells decreased IC50, but increased the cell apoptosis rates and promoted the drug accumulation in cancer cells. Dual‑luciferase activity assay indicated that sorcin was the target of miR‑1 in GC. In addition, overexpression of sorcin could partially reverse the effect of miR‑1 in MDR GC cells. The role of miR‑1 in MDR GC cells makes it a potential therapeutic target for a successful clinical outcome.

Citing Articles

Study on the Chemical Composition and Multidrug Resistance Reversal Activity of (Euphorbiaceae).

Ding Y, Liu Y, Dang Q, Akram Z, Arshad A, Zhu H Int J Mol Sci. 2025; 26(1.

PMID: 39796265 PMC: 11720411. DOI: 10.3390/ijms26010412.

miR-128-3p suppresses tumor growth and enhances chemosensitivity in tongue squamous cell carcinoma through MAP2K7 targeting.

Gupta P, Mallick B Mol Biol Rep. 2024; 51(1):1107.

PMID: 39476205 DOI: 10.1007/s11033-024-10040-7.

Sorcin in Cancer Development and Chemotherapeutic Drug Resistance.

Exertier C, Antonelli L, Fiorillo A, Bernardini R, Colotti B, Ilari A Cancers (Basel). 2024; 16(16).

PMID: 39199583 PMC: 11352664. DOI: 10.3390/cancers16162810.

The role of microRNAs in the gastric cancer tumor microenvironment.

Yu X, Zhang Y, Luo F, Zhou Q, Zhu L Mol Cancer. 2024; 23(1):170.

PMID: 39164671 PMC: 11334576. DOI: 10.1186/s12943-024-02084-x.

Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy.

Peng J, Lin Y, Sheng X, Yuan C, Wang Y, Yin W BMC Cancer. 2024; 24(1):789.

PMID: 38956544 PMC: 11221026. DOI: 10.1186/s12885-024-12500-6.

References

Beale P, Rogers P, Boxall F, Sharp S, Kelland L . BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer. 2000; 82(2):436-40. PMC: 2363292. DOI: 10.1054/bjoc.1999.0939. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

Ilari A, Johnson K, Nastopoulos V, Verzili D, Zamparelli C, Colotti G . The crystal structure of the sorcin calcium binding domain provides a model of Ca2+-dependent processes in the full-length protein. J Mol Biol. 2002; 317(3):447-58. DOI: 10.1006/jmbi.2002.5417. View

Tainton K, Smyth M, Jackson J, Tanner J, Cerruti L, Jane S . Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ. 2004; 11(9):1028-37. DOI: 10.1038/sj.cdd.4401440. View

Ozben T . Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006; 580(12):2903-9. DOI: 10.1016/j.febslet.2006.02.020. View

Yi H, Yang Y, Tang C, Chen Z, Zhang G, Xiao Z . [Sorcin overexpression and multidrug resistance in human gastric cancer cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006; 31(3):340-4, 349. View

de Groot D, van der Deen M, Le T, Regeling A, de Jong S, de Vries E . Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007; 97(8):1077-83. PMC: 2360450. DOI: 10.1038/sj.bjc.6604010. View

Nasser M, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S . Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008; 283(48):33394-405. PMC: 2586284. DOI: 10.1074/jbc.M804788200. View

10.

Deng L, Su T, Leng A, Zhang X, Xu M, Yan L . Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Med Oncol. 2009; 27(4):1102-8. DOI: 10.1007/s12032-009-9342-5. View

11.

Zhang D, Fan D . New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010; 6(4):527-37. DOI: 10.2217/fon.10.21. View

12.

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

13.

He Q, Zhang G, Hou D, Leng A, Xu M, Peng J . Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep. 2010; 25(1):237-43. View

14.

Ye C, Wu W, Yeung J, Li H, Li Z, Wong C . Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett. 2011; 304(2):90-6. DOI: 10.1016/j.canlet.2011.01.025. View

15.

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

16.

Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z . Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 2012; 7(7):e40037. PMC: 3388997. DOI: 10.1371/journal.pone.0040037. View

17.

Koontz M, Horning S, Balise R, Greenberg P, Rosenberg S, Hoppe R . Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol. 2013; 31(5):592-8. PMC: 3565182. DOI: 10.1200/JCO.2012.44.5791. View

18.

Hu Y, Cheng X, Li S, Zhou Y, Wang J, Cheng T . Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol. 2013; 72(4):789-98. DOI: 10.1007/s00280-013-2254-2. View

19.

Hu Y, Li S, Yang M, Yan C, Fan D, Zhou Y . Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Res Treat. 2013; 143(2):287-99. DOI: 10.1007/s10549-013-2809-2. View

20.

Yamagishi N, Nakao R, Kondo R, Nishitsuji M, Saito Y, Kuga T . Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein. Biochem Biophys Res Commun. 2014; 448(4):430-6. DOI: 10.1016/j.bbrc.2014.04.125. View